The Justice Department announced on Thursday that it is easing restrictions on state-licensed medical marijuana, allowing for expanded research and treatment options. Acting Attorney General Todd Blanche revealed via social media that an executive order has been signed to reschedule FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule III. Schedule I drugs, which include heroin and LSD, are considered highly dangerous and are subject to strict regulations, while Schedule III drugs are classified as having a moderate to low potential for dependence. This change is expected to facilitate access to medical marijuana for patients and increase the scope of scientific research into its therapeutic uses.
Why It Matters
The rescheduling of marijuana reflects a significant shift in federal policy regarding cannabis, which has been classified as a Schedule I substance since the 1970s. This designation has historically limited research opportunities and access for patients seeking medical treatment. By moving marijuana to Schedule III, the government acknowledges its potential medicinal benefits, which may lead to broader acceptance and integration of medical marijuana in healthcare. This change follows increasing public support for cannabis reform and a growing body of evidence highlighting its therapeutic applications.
Want More Context? 🔎
